Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
72.38 USD | +1.40% | 0.00% | +76.54% |
06-20 | Dpa-AFX Overview: COMPANIES from 20/06/2024 - 15:15 | DP |
06-20 | Novartis: towards the filing of a buyout offer for MorphoSys | CF |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+76.54% | 2.73B | - | ||
+36.07% | 51.51B | B- | ||
-6.24% | 39.03B | B | ||
+35.14% | 38.91B | A | ||
-10.62% | 26.68B | C | ||
+12.61% | 26.13B | B- | ||
-15.93% | 19.91B | B | ||
+42.38% | 13.71B | B+ | ||
+30.23% | 12.38B | C+ | ||
-3.44% | 11.74B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MOR Stock
- MPSYF Stock
- Ratings MorphoSys AG